Clinical practice guidelines for molecular tumor marker, 2nd edition review part 2

doi:10.1007/s10147-024-02497-0

Practice Guideline

. 2024 May;29(5):512-534.

doi: 10.1007/s10147-024-02497-0. Epub 2024 Mar 17.

Clinical practice guidelines for molecular tumor marker, 2nd edition review part 2

Yoshinori Kikuchi¹, Hideaki Shimada^{2

3}, Fumiyuki Yamasaki⁴, Taku Yamashita⁵, Koji Araki⁶, Kohei Horimoto⁷, Satoshi Yajima⁸, Masakazu Yashiro⁹, Keigo Yokoi¹⁰, Haruhiko Cho¹¹, Takuya Ehira¹², Kazunari Nakahara¹², Hiroshi Yasuda¹², Kazutoshi Isobe¹³, Tetsu Hayashida¹⁴, Shingo Hatakeyama¹⁵, Koichiro Akakura¹⁶, Daisuke Aoki¹⁷, Hiroyuki Nomura¹⁸, Yuji Tada¹⁹, Yuki Yoshimatsu²⁰, Hayato Miyachi²¹, Chiaki Takebayashi²², Ichiro Hanamura²³, Hiroyuki Takahashi²⁴

Affiliations

¹ Department of Clinical Oncology, Toho University, Tokyo, Japan.
² Department of Clinical Oncology, Toho University, Tokyo, Japan. hideaki.shimada@med.toho-u.ac.jp.
³ Department of Surgery, Toho University, Tokyo, Japan. hideaki.shimada@med.toho-u.ac.jp.
⁴ Department of Neurosurgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
⁵ Department of Otorhinolaryngology-Head and Neck Surgery, Kitasato University School of Medicine, Kanagawa, Japan.
⁶ Department of Otorhinolaryngology-Head and Neck Surgery, National Defense Medical College, Saitama, Japan.
⁷ Department of Dermatology, Sapporo Medical University School of Medicine, Sapporo, Japan.
⁸ Department of Surgery, Toho University, Tokyo, Japan.
⁹ Department of Molecular Oncology and Therapeutics, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
¹⁰ Department of Lower Gastrointestinal Surgery, Kitasato University School of Medicine, Kanagawa, Japan.
¹¹ Department of Surgery, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan.
¹² Department of Gastroenterology, St. Marianna University School of Medicine, Kanagawa, Japan.
¹³ Division of Respiratory Medicine, Department of Internal Medicine (Omori), Toho University, Tokyo, Japan.
¹⁴ Department of Surgery, Keio University School of Medicine, Tokyo, Japan.
¹⁵ Department of Urology, Hirosaki University Graduate School of Medicine, Aomori, Japan.
¹⁶ JCHO Mishima General Hospital, Shizuoka, Japan.
¹⁷ International University of Health and Welfare Graduate School, Tokyo, Japan.
¹⁸ Department of Obstetrics and Gynecology, School of Medicine, Fujita Health University, Aichi, Japan.
¹⁹ Department of Pulmonology, School of Medicine, International University of Health and Welfare, Chiba, Japan.
²⁰ Department of Patient-Derived Cancer Model, Tochigi Cancer Center Research Institute, Tochigi, Japan.
²¹ Faculty of Clinical Laboratory Sciences, Nitobe Bunka College, Tokyo, Japan.
²² Division of Hematology and Oncology, Department of Internal Medicine (Omori), Toho University, Tokyo, Japan.
²³ Division of Hematology, Department of Internal Medicine, Aichi Medical University, Aichi, Japan.
²⁴ Department of Pediatrics, Toho University, Tokyo, Japan.

PMID: 38493447
DOI: 10.1007/s10147-024-02497-0

Practice Guideline

Clinical practice guidelines for molecular tumor marker, 2nd edition review part 2

Yoshinori Kikuchi et al. Int J Clin Oncol. 2024 May.

. 2024 May;29(5):512-534.

doi: 10.1007/s10147-024-02497-0. Epub 2024 Mar 17.

Authors

Affiliations

¹ Department of Clinical Oncology, Toho University, Tokyo, Japan.
² Department of Clinical Oncology, Toho University, Tokyo, Japan. hideaki.shimada@med.toho-u.ac.jp.
³ Department of Surgery, Toho University, Tokyo, Japan. hideaki.shimada@med.toho-u.ac.jp.
⁴ Department of Neurosurgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
⁵ Department of Otorhinolaryngology-Head and Neck Surgery, Kitasato University School of Medicine, Kanagawa, Japan.
⁶ Department of Otorhinolaryngology-Head and Neck Surgery, National Defense Medical College, Saitama, Japan.
⁷ Department of Dermatology, Sapporo Medical University School of Medicine, Sapporo, Japan.
⁸ Department of Surgery, Toho University, Tokyo, Japan.
⁹ Department of Molecular Oncology and Therapeutics, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
¹⁰ Department of Lower Gastrointestinal Surgery, Kitasato University School of Medicine, Kanagawa, Japan.
¹¹ Department of Surgery, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan.
¹² Department of Gastroenterology, St. Marianna University School of Medicine, Kanagawa, Japan.
¹³ Division of Respiratory Medicine, Department of Internal Medicine (Omori), Toho University, Tokyo, Japan.
¹⁴ Department of Surgery, Keio University School of Medicine, Tokyo, Japan.
¹⁵ Department of Urology, Hirosaki University Graduate School of Medicine, Aomori, Japan.
¹⁶ JCHO Mishima General Hospital, Shizuoka, Japan.
¹⁷ International University of Health and Welfare Graduate School, Tokyo, Japan.
¹⁸ Department of Obstetrics and Gynecology, School of Medicine, Fujita Health University, Aichi, Japan.
¹⁹ Department of Pulmonology, School of Medicine, International University of Health and Welfare, Chiba, Japan.
²⁰ Department of Patient-Derived Cancer Model, Tochigi Cancer Center Research Institute, Tochigi, Japan.
²¹ Faculty of Clinical Laboratory Sciences, Nitobe Bunka College, Tokyo, Japan.
²² Division of Hematology and Oncology, Department of Internal Medicine (Omori), Toho University, Tokyo, Japan.
²³ Division of Hematology, Department of Internal Medicine, Aichi Medical University, Aichi, Japan.
²⁴ Department of Pediatrics, Toho University, Tokyo, Japan.

PMID: 38493447
DOI: 10.1007/s10147-024-02497-0

Abstract

In recent years, rapid advancement in gene/protein analysis technology has resulted in target molecule identification that may be useful in cancer treatment. Therefore, "Clinical Practice Guidelines for Molecular Tumor Marker, Second Edition" was published in Japan in September 2021. These guidelines were established to align the clinical usefulness of external diagnostic products with the evaluation criteria of the Pharmaceuticals and Medical Devices Agency. The guidelines were scoped for each tumor, and a clinical questionnaire was developed based on a serious clinical problem. This guideline was based on a careful review of the evidence obtained through a literature search, and recommendations were identified following the recommended grades of the Medical Information Network Distribution Services (Minds). Therefore, this guideline can be a tool for cancer treatment in clinical practice. We have already reported the review portion of "Clinical Practice Guidelines for Molecular Tumor Marker, Second Edition" as Part 1. Here, we present the English version of each part of the Clinical Practice Guidelines for Molecular Tumor Marker, Second Edition.

Keywords: Cancer; Driver genes; Tumor markers.

PubMed Disclaimer

Cited by

Clinical Impact of Olaparib for Platinum-Sensitive Recurrent Ovarian Cancer.
Ishida H, Manrai M, Takashima A, Egashira H, Nonaka M, Shimada H. Ishida H, et al. Diseases. 2025 Feb 10;13(2):51. doi: 10.3390/diseases13020051. Diseases. 2025. PMID: 39997058 Free PMC article.
Malignant transformation of an ovarian mature teratoma diagnosed 17 years ago: a case report and literature review of treatment with immune checkpoint inhibitors.
Nagayama A, Miyagawa C, Kashima Y, Ohta M, Otani T, Kurosaki T, Isomoto K, Inagaki C, Takahama T, Yonesaka K, Hayashi H, Sakai K, Nishio K, Nakagawa K, Matsumura N. Nagayama A, et al. Int Cancer Conf J. 2024 Dec 19;14(2):85-90. doi: 10.1007/s13691-024-00740-z. eCollection 2025 Apr. Int Cancer Conf J. 2024. PMID: 40160882

References

1. Bence Jones H (1847) Chemical pathology. Lancet 2:88 - DOI
1. Abelev GI, Perove SD, Khramkova NI et al (1963) Production of embryonal alpha-globin by transplantable mouse hepatoma. Transplantation 1:174–180 - PubMed - DOI
1. Gold P, Freedman SO (1965) Specific carcinoembryonic antigens of the human digestive system. J Exp Med 122(3):467–481 - PubMed - PMC - DOI
1. Jeyakumar A, Younis T (2012) Trastuzumab for HER2-positive metastatic breast cancer: clinical and economic considerations. Clin Med Insights Oncol 6:179–187 - PubMed - PMC - DOI
1. Cohen P, Cross D, Jänne PA (2021) Kinase drug discovery 20 years after imatinib: progress and future directions. Nat Rev Drug Discov 20(7):551–569 - PubMed - PMC - DOI

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Springer
Medical
- MedlinePlus Health Information

[1] Bence Jones H (1847) Chemical pathology. Lancet 2:88 - DOI

[2] Bence Jones H (1847) Chemical pathology. Lancet 2:88 - DOI

[3] Abelev GI, Perove SD, Khramkova NI et al (1963) Production of embryonal alpha-globin by transplantable mouse hepatoma. Transplantation 1:174–180 - PubMed - DOI

[4] Abelev GI, Perove SD, Khramkova NI et al (1963) Production of embryonal alpha-globin by transplantable mouse hepatoma. Transplantation 1:174–180 - PubMed - DOI

[5] Gold P, Freedman SO (1965) Specific carcinoembryonic antigens of the human digestive system. J Exp Med 122(3):467–481 - PubMed - PMC - DOI

[6] Gold P, Freedman SO (1965) Specific carcinoembryonic antigens of the human digestive system. J Exp Med 122(3):467–481 - PubMed - PMC - DOI

[7] Jeyakumar A, Younis T (2012) Trastuzumab for HER2-positive metastatic breast cancer: clinical and economic considerations. Clin Med Insights Oncol 6:179–187 - PubMed - PMC - DOI

[8] Jeyakumar A, Younis T (2012) Trastuzumab for HER2-positive metastatic breast cancer: clinical and economic considerations. Clin Med Insights Oncol 6:179–187 - PubMed - PMC - DOI

[9] Cohen P, Cross D, Jänne PA (2021) Kinase drug discovery 20 years after imatinib: progress and future directions. Nat Rev Drug Discov 20(7):551–569 - PubMed - PMC - DOI

[10] Cohen P, Cross D, Jänne PA (2021) Kinase drug discovery 20 years after imatinib: progress and future directions. Nat Rev Drug Discov 20(7):551–569 - PubMed - PMC - DOI

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Clinical practice guidelines for molecular tumor marker, 2nd edition review part 2

Affiliations

Clinical practice guidelines for molecular tumor marker, 2nd edition review part 2

Authors

Affiliations

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Medical